Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| And so this is really a big advantage from our procedure |
| We are poised for a very exciting year for Anavex |
| I think if I can start with the last part, there’s not such a thing actually the trial was really showing an extremely nice improvement score in the active arm with over minus 12.9 in our analysis, which is extremely strong |
| Again, this is exciting progress in the field relating to treating neurodegenerative diseases highlights the significant potential for our broad therapeutic portfolio and differentiated precision medicine platform to deliver easy access and scalable treatment options demonstrated by the initiated process of Marketing Authorisation Application to the European Medicine Agency, EMA for blarcamesine related to the treatment of Alzheimer’s disease |
| And we have, again, a strong interest from the community, given the strong interest, and to continue to stay on study drug and patients in Rett syndrome from our program have been now on this drug for over four years – up to four years |
| This is very good news and this data also expands the safety objectives met in this first in human study of ANAVEX3-71, further supporting its drug development program |
| And as far as Rett goes, what I sort of heard you say was given that the data for a A2-73 was even better than the drug that recently got approved, except for how the placebo went |
| Not only have we demonstrated to continue to be fiscally responsible, but this is also an exciting time for the company and we’re very excited to be entering a new phase of the company’s history with our biomarker driven precision medicine programs |
| A high enrollment rate into the OLE open-label extension of over 91%, as well as the high level of requests for the Compassionate Use Program of 93%, provide solid numerical evidence for the positive real world evidence reported by patients and their caregivers with Rett syndrome under Compassionate Use Authorization |
| So we showed a stronger signal in the active arm |
| For Fragile X, we believe new disease specific translatable and objective biomarker data generated recently with ANAVEX2-73 should be strengthening the support for the initiation of the potentially pivotal ANAVEX2-73 Phase 2/3 clinical trial in Fragile X |
| That really shows a very high sticky interest to keep our drug and not to switch to anything else in the meantime |
| And this gives us actually probably an interesting position from a timing perspective, to prepare now a dialogue with the agency to share our data with the small molecule, which has the advantage of being easily administrable, does not have any challenging procedures |
| I’m pleased to share with you today our first quarter financial results for our 2024 fiscal year |
| And these measures are very noisy, as we have noticed |
| We measured a better in the brain, but it was not an entry criteria |
| Great |
| Related to ANAVEX3-71, our second clinical small molecule, we were pleased to announce the initiation of the U.S |
| Where do you stand with the FDA as far as Alzheimer’s goes? I was really pleased with the news about the EMA, but what about the FDA? Christopher Missling Yes, it’s a great question |
| We continue to focus on execution and commercial readiness, as we advance our therapeutic pipeline to potentially improve patients’ lives living with neurodegenerative, neurodevelopmental disorders and schizophrenia |
| And lastly, also last month, we announced the expansion and strengthening of our patent portfolio with the United States Patent and Trademark Office granted a new U.S |
| What happened was in our trial, the placebo also improved and in the trofinetide the placebo did not improve |
| Overall, we plan to continue to be fiscally responsible and we believe we continue to have sufficient cash runway to fund operations and clinical programs beyond the next four years |
| At our current cash utilization rate, we believe we continue to have sufficient cash runway to fund operations and clinical programs beyond the next four years |
| Christopher Missling Thank you, Clint, and good morning, everyone |
| Thank you |
| Thank you |
| Thank you |
| Christopher Missling Thank you |
| Christopher Missling Thank you |
| Statement |
|---|
| That tells us that the antibodies indeed seem to be not easy, well received in the community, or the procedures are very cumbersome, or the pet centers are not able to accommodate patients, or the MRI centers are not able to schedule at a time |
| And lastly, we reported a net loss of $8.6 million for the quarter or $0.11 share |
| So we saw that in the last quarter, they were not able to reach their target numbers of patients on drug in the market |
| And these 30 patients, if a few of them are just basically very noisy, that could derail and increase the noise in the trial and increase the standard error, which we saw in our trial |
| These factors may include without limitation risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights |
| And trofinetide showed only an improvement in the active arm of minus 5.1 |
| So it’s a combination of factors which I cannot really talk about, but seems to be really not an easy task |
Please consider a small donation if you think this website provides you with relevant information